Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-04-30

Study Completion Date

2016-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients

NCT03344822

Prostate Cancer

UNKNOWN PHASE2/PHASE3

Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

NCT03439033

Prostate Cancer

TERMINATED PHASE2

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882

Prostate Cancer

COMPLETED PHASE2

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

NCT05079828

Prostate Cancer

COMPLETED NA

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

NCT03768349

Prostate Cancer

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval.

No adverse events are expected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

F-18-FCH & Ga-68-NODAGA-MJ9

1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9

Intervention Type DIAGNOSTIC_TEST

Each patient will have two PET/CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9

Each patient will have two PET/CT

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1 PET/CT with F-18-FCH 1 PET/CT with Ga-68-NODAGA-MJ9

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age : adult patients
* Karnofsky : ≥ 80%
* Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT is indicated for primary cancer staging, or for recurrence with increase of blood PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or more in post initial curative intent surgery will be required.
* Signed informed consent.